




RealRate

PHARMACEUTICAL 2024

Hepion Pharmaceuticals Inc
Rank 263 of 309



The relative strengths and weaknesses of Hepion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 8.4% points. The greatest weakness of Hepion Pharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 93%, being 120% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	17,488
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,290
Liabilities, Non-Current	93
Other Assets	577
Other Compr. Net Income	11
Other Expenses	2,790
Other Liabilities	5,430
Other Net Income	-878
Other Revenues	0
Property and Equipment	29
Research and Development	35,640
Selling, General and Administrative Expense	9,618

Output Variable	Value in 1000 USD
Assets	18,094
Liabilities	10,814
Expenses	48,048
Revenues	0
Stockholders Equity	7,281
Net Income	-48,926
Comprehensive Net Income	-48,920
BaseVar	38,923
ECR before LimitedLiability	-229%
Economic Capital Ratio	93%